What does the mechanism of semaglutide predict that FLOW did not test?

The particulars: semaglutide · FLOW.

The empirical answer seems settled. The explanation does not.

If the honest answer is that nobody knows, I would rather hear that than a plausible story.

Why does this happen, and what would falsify the usual explanation?

Answering this needs the distinction between the native hormone and the pharmacological agents, whose half-lives differ by three orders of magnitude and whose effects therefore differ in kind.

Albumin binding does the rest of the work. A fatty-acid chain attached through a linker binds circulating albumin reversibly, which both shields the peptide from renal clearance and creates a depot; that is how a two-minute hormone becomes a once-weekly drug.

Mass shifts and what they usually mean

Specifically, native GLP-1 has a circulating half-life of one to two minutes because dipeptidyl peptidase-4 cleaves the two N-terminal residues. Substituting the position-8 alanine, as the long-acting analogues do, blocks that cleavage and is the single most consequential modification in the class.

The half-life problem and the albumin-binding solution are the whole story of the class chemically.

The short version: glucose-dependent insulinotropic action, glucagon suppression, delayed gastric emptying and central appetite effects, from one receptor in four places.

Central effects reach the arcuate nucleus and the area postrema, regions with an incomplete blood-brain barrier. That anatomy is why a large peptide can act centrally at all, and it also explains the nausea, since the area postrema is the chemoreceptor trigger zone.

Receptor density and downstream coupling differ between tissues, so the dose-response curves for glycaemia, weight and nausea are not the same curve. That is the pharmacological basis for titration.

Structural work on the receptor by cryo-electron microscopy has resolved the agonist-bound active state and is the basis for current structure-guided design in this class.

Nausea and appetite share an anatomy, which is why they are hard to separate by dose.

edited 29 Jun 2025 by bea_castellanos — removed a claim I could not source

The honest answer is that appetite suppression is centrally mediated and gastric emptying is peripheral, and the two contribute different amounts in different people.

Glucagon suppression is also glucose-dependent and is lost during hypoglycaemia, which preserves the counter-regulatory response — a genuinely elegant piece of physiology and the reason the class is safe in this respect.

Worth being precise here: gastric emptying delay attenuates with continued exposure for long-acting agents through receptor desensitisation, which is why the early nausea usually settles while the appetite effect persists.

Glucose-dependence is the property to remember; it explains the safety profile on its own.

The endogenous hormone is degraded by dipeptidyl peptidase-4 within a couple of minutes. Every long-acting agent in this class is essentially an answer to that one problem.

Biased agonism — differential recruitment of beta-arrestin versus G-protein signalling — is an active research area and is one hypothesis for why agents with similar receptor affinity have different tolerability.

Area postrema involvement in nausea from this class is supported by lesion studies in animals and by the anatomy of the circumventricular organs.

Research-use material is not approved for human use, and mechanism is not a safety argument.

Mechanism is a good guide to what to expect and a poor guide to how much.

This is answerable mechanistically, and the mechanism actually predicts the side-effect profile, which is unusual and worth exploiting when reasoning about it.

Glucose-dependence arises because the insulinotropic signal amplifies glucose-stimulated secretion rather than initiating secretion. With no glucose signal to amplify, there is little to amplify.

The caveat is that mechanism predicts direction and rarely predicts magnitude in an individual, and people reason from mechanism to dose far too confidently.

Tissue distribution first, then signalling. Nearly every question in this tag resolves at the first step.

edited 28 Aug 2025 by Dr_Tomas_Kral — updated for the 2026 guidance change